Flagship explainer
How ALNYLAM PHARMACEUTICALS, INC. makes its money
Start with a dollar of revenue and follow what the filing says remains.
Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.
| Filed line | Value | % of revenue | Source |
|---|---|---|---|
| $3.7B | 100% |
| |
| Cost of revenue | $677M | 18% |
|
| $3.0B | 82% |
| |
| $502M | 14% |
| |
| Income before tax | $323M | 9% |
|
| Income tax | $9.4M | 0% |
|
| $314M | 8% |
|
Source:
- SEC filing · FY 2025Filing detailsAccession 0001628280-26-007497